Ultravist Injection Side Effects
Please note - some side effects for Ultravist Injection may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Ultravist Injection Side Effects - for the Professional
Applies to: intra-arterial injection
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.
The following table of incidence of reactions is based upon controlled clinical trials in which Ultravist Injection was administered to 1142 patients. This listing includes all reported adverse reactions regardless of attribution.
Adverse reactions are listed by System Organ Class and in decreasing order of occurrence for rates greater than 1% in the ULTRAVIST group.
|Table 3: ADVERSE REACTIONS REPORTED IN > 1% OF PATIENTS WHO RECEIVED Ultravist Injection IN CLINICAL TRIALS|
|System Organ Class||Adverse Reaction||Ultravist Injection|
|N= 1142 (%)|
|Nervous system disorders||Headache||46 (4)|
|Eye disorders||Abnormal Vision||12 (1.1)|
|Cardiac disorders||Chest pain||18 (1.6)|
|Vascular disorders||Vasodilatation||30 (2.6)|
|Gastrointestinal disorders||Nausea||42 (3.7)|
|Musculoskeletal and connective tissue disorders||Back pain||22 (1.9)|
|Renal and urinary disorders||Urinary urgency||21 (1.8)|
|General disorders and administration site conditions||
Injection site and infusion site reactions (hemorrhage, hematoma, pain, edema, erythema, rash)
One or more adverse reactions were recorded in 273 of 1142 (24%) patients during the clinical trials, coincident with the administration of Ultravist Injection or within the defined duration of the study follow-up period (24–72 hours). Ultravist Injection is often associated with sensations of warmth and/or pain.
Serious, life-threatening and fatal reactions have been associated with the administration of iodine-containing contrast media, including Ultravist Injection. In clinical trials 7/1142 patients given Ultravist Injection died 5 days or later after drug administration. Also, 10/1142 patients given Ultravist Injection had serious adverse events.
The following adverse reactions were observed in ≤1% of the subjects receiving Ultravist Injection:
Cardiac disorders: atrio ventricular block (complete), bradycardia, ventricular extrasystole;
Gastrointestinal disorders: abdominal discomfort, abdominal pain, abdominal pain upper, constipation, diarrhea, dry mouth, dyspepsia, gastrointestinal disorder, gastrointestinal pain, salivation increased, stomach discomfort, rectal tenesmus;
General disorders and administration site conditions: asthenia, chest discomfort, chills, excessive thirst, extravasation, feeling hot, hyperhydrosis, malaise, edema peripheral, pyrexia;
Immune system disorders: asthma, face edema;
Investigations: blood lactate dehydrogenase increased, blood urea increased, hemoglobin increased, white blood cell count increased;
Musculoskeletal and connective tissue disorders: arthralgia, musculoskeletal pain, myasthenia, neck pain, pain in extremity;
Nervous system disorders: agitation, confusion, convulsion, dizziness, hypertonia, hypesthesia, incoordination, neuropathy, somnolence, speech disorder, tremor, paresthesia, visual field defect;
Psychiatric disorders: anxiety;
Renal and urinary disorders: dysuria, renal pain, urinary retention;
Respiratory, thoracic and mediastinal disorders: apnea, cough increased, dyspnea, hypoxia, pharyngeal edema, pharyngitis, pleural effusion, pulmonary hypertension, respiratory disorder, sore throat;
Skin and subcutaneous tissue disorders: erythema, pruritus, rash, urticaria;
Vascular disorders: coronary artery thrombosis, flushing, hypertension, hypotension, peripheral vascular disorder, syncope, vascular anomaly.
The following adverse reactions have been identified during post approval use of Ultravist Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions reported in foreign postmarketing surveillance and other trials with the use of Ultravist Injection include:
Cardiac disorders: cardiac arrest, ventricular fibrillation, atrial fibrillation, tachycardia, palpitations, congestive heart failure, myocardial infarction, angina pectoris;
Ear and labyrinth disorders: vertigo, tinnitus;
Endocrine disorders: hyperthyroidism, thyrotoxic crisis, hypothyroidism;
Eye disorders: mydriasis, lacrimation disorder;
Gastrointestinal disorders: dysphagia, swelling of salivary glands;
Immune system disorders: anaphylactoid reaction (including fatal cases), respiratory arrest, anaphylactoid shock, angioedema, laryngeal edema, laryngospasm, bronchospasm, hypersensitivity;
Nervous system disorders: cerebral ischemia/infarction, paralysis, paresis, transient cortical blindness, aphasia, coma, unconsciousness, amnesia, hypotonia;
Renal and urinary disorders: renal failure, hematuria;
Respiratory, thoracic and mediastinal disorders: pulmonary edema, acute respiratory distress syndrome, asthma;
Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome, skin discoloration;
Vascular disorders: vasospasm.
The overall character, quality, and severity of adverse reactions in pediatric patients are generally similar to those reported in adult patients. Additional adverse reactions reported in pediatric patients from foreign marketing surveillance or other information are: epistaxis, angioedema, migraine, joint disorder (effusion), muscle cramps, mucous membrane disorder (mucosal swelling), conjunctivitis, hypoxia, fixed eruptions, vertigo, diabetes insipidus, and brain edema. [See Use in Specific Populations (8.4).]
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.